DossierENTITY

Fabhalta

Coverage of Fabhalta in the Nexus archive.

Earliest in view: Jul 17 · 17:47 UTCMost recent: Jul 17 · 17:47 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHJul 17 · 17:47 UTCMEDPAGE TODAY
First Complement Inhibitor Wins Full Approval in IgA Nephropathy
The FDA fully approved iptacopan (Fabhalta), a complement inhibitor, to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of progression. Novartis announced the approval, marking the first complement inhibitor approved for this condition.